Stock listing
NASDAQ:ACRV Acrivon Therapeutics, Inc. Stock
Home listing (NASDAQ) of Acrivon Therapeutics, Inc.
Follow Acrivon Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ACRV
$1.15 USD -0.25 (-17.9%)
Close on Nov 20, 2026
- Day range
- $0.971 – $1.40 USDNov 20, 2026
- Volume
- 1.29M sharesNov 20, 2026
- Market cap
- $49.35M USDAt the close on Nov 20, 2026 · price × 42.91M shares outstanding
- 52-week range
- $0.971 – $3.56 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $504,941 USDMedian day 223,250 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACRV · Home | $1.15 USD | -0.25 (-17.9%) | 1,294,096 | $1.40 | $1.40 | $0.971 | $1.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACRV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.15 | -0.25 | -17.9% | $1.40 | $1.40 | $0.971 | 1,294,096 | |
| $1.40 | -0.16 | -10.3% | $1.59 | $1.59 | $1.40 | 375,006 | |
| $1.56 | +0.13 | +9.1% | $1.44 | $1.60 | $1.44 | 612,608 | |
| $1.43 | -0.03 | -2.1% | $1.45 | $1.56 | $1.39 | 428,288 | |
| $1.46 | +0.01 | +0.7% | $1.43 | $1.49 | $1.40 | 343,021 | |
| $1.45 | -0.01 | -0.7% | $1.47 | $1.50 | $1.40 | 199,700 | |
| $1.46 | -0.11 | -7.0% | $1.60 | $1.60 | $1.44 | 334,500 | |
| $1.57 | 0.00 | 0.0% | $1.57 | $1.65 | $1.55 | 218,300 | |
| $1.57 | -0.01 | -0.6% | $1.57 | $1.65 | $1.55 | 81,200 | |
| $1.58 | -0.03 | -1.9% | $1.61 | $1.70 | $1.56 | 229,500 | |
| $1.61 | +0.04 | +2.5% | $1.50 | $1.70 | $1.48 | 364,500 | |
| $1.57 | -0.17 | -9.8% | $1.73 | $1.73 | $1.51 | 314,300 | |
| $1.74 | +0.07 | +4.2% | $1.69 | $1.77 | $1.65 | 127,900 | |
| $1.67 | +0.06 | +3.7% | $1.61 | $1.67 | $1.61 | 133,800 | |
| $1.61 | -0.05 | -3.0% | $1.66 | $1.707 | $1.58 | 228,200 | |
| $1.66 | -0.10 | -5.7% | $1.74 | $1.76 | $1.65 | 165,700 | |
| $1.76 | -0.03 | -1.7% | $1.80 | $1.85 | $1.71 | 110,500 | |
| $1.79 | +0.05 | +2.9% | $1.69 | $1.79 | $1.678 | 133,200 | |
| $1.74 | +0.02 | +1.2% | $1.73 | $1.78 | $1.63 | 168,500 | |
| $1.72 | -0.01 | -0.6% | $1.74 | $1.77 | $1.69 | 259,100 | |
| $1.73 | -0.03 | -1.7% | $1.76 | $1.82 | $1.68 | 108,200 | |
| $1.76 | -0.065 | -3.6% | $1.84 | $1.86 | $1.72 | 90,200 | |
| $1.825 | +0.03 | +1.7% | $1.80 | $1.88 | $1.80 | 159,100 | |
| $1.795 | +0.105 | +6.2% | $1.78 | $1.82 | $1.75 | 185,000 | |
| $1.69 | +0.05 | +3.0% | $1.68 | $1.74 | $1.63 | 122,200 | |
| $1.64 | -0.12 | -6.8% | $1.75 | $1.77 | $1.63 | 262,100 | |
| $1.76 | +0.04 | +2.3% | $1.74 | $1.80 | $1.71 | 114,500 | |
| $1.72 | -0.03 | -1.7% | $1.73 | $1.81 | $1.70 | 214,600 | |
| $1.75 | -0.15 | -7.9% | $1.86 | $1.872 | $1.74 | 477,200 | |
| $1.90 | -0.01 | -0.5% | $1.91 | $1.929 | $1.87 | 140,200 | |
| $1.91 | +0.04 | +2.1% | $1.88 | $1.955 | $1.862 | 192,000 | |
| $1.87 | -0.01 | -0.5% | $1.89 | $1.905 | $1.78 | 419,700 | |
| $1.88 | +0.02 | +1.1% | $1.85 | $1.913 | $1.82 | 283,500 | |
| $1.86 | -0.12 | -6.1% | $2.00 | $2.07 | $1.85 | 158,300 | |
| $1.98 | -0.01 | -0.5% | $1.99 | $2.035 | $1.91 | 402,100 | |
| $1.99 | -0.02 | -1.0% | $2.05 | $2.06 | $1.99 | 205,100 | |
| $2.01 | -0.04 | -2.0% | $2.02 | $2.12 | $2.00 | 316,900 | |
| $2.05 | -0.03 | -1.4% | $2.09 | $2.16 | $2.04 | 175,100 | |
| $2.08 | +0.02 | +1.0% | $2.05 | $2.12 | $2.05 | 132,500 | |
| $2.06 | -0.04 | -1.9% | $2.08 | $2.12 | $2.025 | 231,000 | |
| $2.10 | -0.02 | -0.9% | $2.12 | $2.13 | $2.07 | 181,900 | |
| $2.12 | +0.06 | +2.9% | $2.10 | $2.15 | $2.04 | 316,700 | |
| $2.06 | -0.09 | -4.2% | $2.14 | $2.17 | $2.025 | 433,200 | |
| $2.15 | +0.14 | +7.0% | $2.04 | $2.24 | $2.01 | 572,500 | |
| $2.01 | +0.16 | +8.6% | $1.89 | $2.025 | $1.871 | 333,900 | |
| $1.85 | +0.15 | +8.8% | $1.71 | $1.895 | $1.69 | 477,400 | |
| $1.70 | 0.00 | 0.0% | $1.74 | $1.77 | $1.67 | 463,700 | |
| $1.70 | -0.13 | -7.1% | $1.85 | $1.90 | $1.695 | 764,300 | |
| $1.83 | -0.13 | -6.6% | $1.97 | $1.975 | $1.805 | 303,700 | |
| $1.96 | -0.04 | -2.0% | $1.98 | $1.99 | $1.94 | 208,200 | |
| $2.00 | -0.04 | -2.0% | $2.05 | $2.06 | $1.95 | 461,600 | |
| $2.04 | +0.05 | +2.5% | $2.03 | $2.06 | $1.96 | 323,900 | |
| $1.99 | -0.11 | -5.2% | $2.10 | $2.17 | $1.99 | 238,800 | |
| $2.10 | -0.03 | -1.4% | $2.13 | $2.175 | $2.07 | 126,400 | |
| $2.13 | +0.07 | +3.4% | $2.06 | $2.14 | $2.055 | 184,500 | |
| $2.06 | -0.09 | -4.2% | $2.15 | $2.15 | $2.045 | 118,800 | |
| $2.15 | +0.08 | +3.9% | $2.07 | $2.20 | $2.05 | 131,100 | |
| $2.07 | -0.02 | -1.0% | $2.07 | $2.125 | $2.025 | 356,500 | |
| $2.09 | +0.03 | +1.5% | $2.04 | $2.11 | $2.021 | 160,100 | |
| $2.06 | -0.09 | -4.2% | $2.16 | $2.19 | $2.05 | 217,100 | |
| $2.15 | +0.07 | +3.4% | $2.11 | $2.20 | $2.08 | 188,300 | |
| $2.08 | -0.10 | -4.6% | $2.17 | $2.19 | $2.08 | 160,100 | |
| $2.18 | -0.02 | -0.9% | $2.19 | $2.255 | $2.17 | 242,700 | |
| $2.20 | -0.01 | -0.5% | $2.19 | $2.225 | $2.06 | 171,000 | |
| $2.21 | +0.01 | +0.5% | $2.21 | $2.31 | $2.18 | 360,800 | |
| $2.20 | -0.19 | -7.9% | $2.33 | $2.37 | $2.17 | 499,200 |
- Ticker
- NASDAQ:ACRV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
Latest deck · Nov 20, 2026
Technical Presentation (November 2026)
Technical · 14 slides
Latest news
Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 16, 2026
Closed $1.43 (-2.1%) on Nov 17, 2026
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Nov 6, 2026
Closed $1.61 (+2.5%) on Nov 6, 2026
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nov 4, 2026
Closed $1.57 (-9.8%) on Nov 5, 2026
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Oct 29, 2026
Closed $1.76 (-1.7%) on Oct 29, 2026
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Oct 20, 2026
Closed $1.80 (+6.2%) on Oct 20, 2026
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Sep 2, 2026
Closed $2.15 (+3.9%) on Sep 2, 2026
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Aug 31, 2026
Closed $2.09 (+1.5%) on Aug 31, 2026
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Aug 12, 2026
Closed $1.85 (+7.6%) on Aug 13, 2026
Acrivon Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 74 in all · newest Nov 16, 2026 · oldest 2023
- Decks
- 18 decks · latest Nov 20, 2026
Where Acrivon Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACRV · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ACRV | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 1.7×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$26.60M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.09
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.07M | US$13.13M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Aptamer Sciences, Inc. · KRX:291650 | US$49.50M | US$34.66M | n/a | 8.6× | n/a | 1.6× | −215.8% | 0.0× | n/a |
| SYNTHAVERSE Spolka Akcyjna · GPW:SVE | US$48.68M | US$70.98M | n/a | 5.9× | n/a | 1.7× | −43.1% | 0.8× | n/a |
| Heron Therapeutics, Inc. · NASDAQ:HRTX | US$48.04M | US$156.3M | n/a | 1.1× | n/a | 9.8× | −14.5% | 26.8× | 1.93 |
| Helix BioPharma Corp. · TSX:HBP | US$47.94M | US$50.27M | n/a | n/a | n/a | 4.8× | n/a | 0.3× | 0.36 |
| Oncolytics Biotech Inc. · NASDAQ:ONCY | US$47.66M | US$45.23M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Median of the others | US$50.10M | US$47.75M | 4.9× | 1.7× | −129.4% | 0.0× | 1.38 |
Forecasts
4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.86 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Adam D. Levy | Chief Financial Officer |
| Eric Devroe | Chief Operating Officer |
| Mary-Alice Miller | Chief Legal Officer |
| Caroline Wigerup | Vice President, Research and Business Operations |
| Kristina Masson | Co-Founder, EVP, Business Operations, Site Head, Director |
| Erick Gamelin | Chief Development Officer |
| Mansoor Raza Mirza | Chief Medical Officer |
| Michaela Levin | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Charles Baum | Director |
| Derek DiRocco | Director |
| Ivana Magovčević-Liebisch | Director |
| Kristina Masson | Co-Founder, EVP, Business Operations, Site Head, Director |
| Michael Tomsicek | Director |
| Peter Blume-Jensen | Director |
| Santhosh Palani | Director |
| Sharon Shacham | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −2.0% |
| Q2 2026 | Aug 12, 2026 · After close | +7.6% |
| Q1 2026 | May 13, 2026 · After close | 0.0% |
| Q4 2025 | Mar 19, 2026 | +1.2% |
| Q3 2025 | Nov 13, 2025 · After close | +8.2% |
| Q2 2025 | Aug 14, 2025 · After close | −2.9% |
| Q1 2025 | May 14, 2025 · After close | −3.5% |
| Q4 2024 | Mar 27, 2025 | −14.2% |
| Q3 2024 | Nov 13, 2024 · Before open | −5.5% |
| Q2 2024 | Aug 13, 2024 · Before open | −4.5% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −1.4% |
| Q4 2023 | Mar 28, 2024 · Before open | +10.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −19.2% |
| Q2 2023 | Aug 11, 2023 · Before open | +6.8% |
| Q1 2023 | May 9, 2023 · Before open | +6.8% |
| Q4 2022 | Mar 28, 2023 · Before open | −1.8% |
| Q3 2022 | Dec 15, 2022 · After close | +4.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 14 slides | Nov 20, 2026 |
| Technical Presentation (November 2026) | Technical | 30 slides | Nov 10, 2026 |
| Investor Presentation (September 2026) | Investor deck | 50 slides | September 2026 |
| Technical Presentation (July 2026) | Technical | 15 slides | July 2026 |
| Investor Presentation (March 2026) | Investor deck | 48 slides | Mar 19, 2026 |
| TD Cowen Healthcare Conference 2026 | Conference | 9 slides | Mar 2, 2026 |
| Corporate Update (February 2026) | Corporate update | 13 slides | Feb 27, 2026 |
| Corporate Update (January 2026) | Corporate update | 31 slides | Jan 8, 2026 |
| Investor Presentation (September 2025) | Investor deck | 57 slides | Sep 5, 2025 |
| Investor Day (March 2025) | Investor day | 48 slides | Mar 25, 2025 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2024) | Technical | 45 slides | Sep 16, 2024 |
| Investor Day (April 2024) | Investor day | 42 slides | Apr 24, 2024 |
| Investor Presentation (January 2024) | Investor deck | 60 slides | Jan 8, 2024 |
| Corporate Update (November 2023) | Corporate update | 56 slides | Nov 9, 2023 |
| Investor Presentation (September 2023) | Investor deck | 49 slides | Sep 5, 2023 |
| Investor Day (May 2023) | Investor day | 34 slides | May 1, 2023 |
| Investor Presentation (April 2023) | Investor deck | 41 slides | Apr 25, 2023 |
| Corporate Update (March 2023) | Corporate update | 40 slides | Mar 13, 2023 |
IPO
Priced at US$12.50 a share on Nov 14, 2022.
- Price
- US$12.50 a share
- Shares offered
- 7,550,000 shares of common stock
- Offering size
- US$94.4 million
- Underwriters' option
- Up to 1,132,500 more shares
- Underwriters
- JEFFERIES, COWEN, PIPER SANDLER · In the order on the cover
- Shares delivered
- On or about Nov 17, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 12, 2022 |
| Filed publicly | Oct 17, 2022 |
| Amended twice | Newest Nov 8, 2022 |
| Shares registered with an exchange | Nov 7, 2022 |
| Declared effective by the SEC | Nov 9, 2022 |
| Final prospectus, with the price | Nov 16, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 16, 2022 |
| S-1MEF · Registration of more shares for the same offering | Nov 14, 2022 |
| FWP · Free writing prospectus | Nov 14, 2022 |
| EFFECT · Notice that a registration is effective | Nov 9, 2022 |
| CERT · Exchange's certificate of listing | Nov 8, 2022 |
| S-1/A · Registration statement, amended | Nov 8, 2022 |
| CORRESP · Letter to the SEC | Nov 7, 2022 |
| CORRESP · Letter to the SEC | Nov 7, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 7, 2022 |
| S-1/A · Registration statement, amended | Nov 3, 2022 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 17, 2022 |
| S-1 · Registration statement | Oct 17, 2022 |
| UPLOAD · Letter from the SEC | Oct 5, 2022 |
| DRSLTR · Letter to the SEC with a draft | Sep 22, 2022 |
| DRS/A · Draft registration statement, amended | Sep 22, 2022 |
| UPLOAD · Letter from the SEC | Sep 12, 2022 |
| DRS · Draft registration statement | Aug 12, 2022 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 16, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.36M | 1.01M | 536.0K | 1.09M | 832.0K | 13.0K |
| Gross profit | -1.36M | -1.01M | -536.0K | -1.09M | -832.0K | -13.0K |
| Research and development | 60.0M | 64.0M | 46.0M | 23.9M | 13.7M | 1.87M |
| Selling, general and administrative | 24.1M | 25.2M | 21.1M | 8.71M | 2.47M | 1.30M |
| Operating income | -84.1M | -89.2M | -67.1M | -32.7M | -16.2M | -3.17M |
| Depreciation and amortization | 1.36M | 1.01M | 536.0K | 364.0K | 37.0K | 13.0K |
| EBITDA | -82.8M | -88.2M | -66.6M | -32.3M | -16.1M | -3.15M |
| Interest expense | 1.49M | 59.0K | ||||
| Income before tax | -77.8M | -80.4M | -60.4M | -31.2M | -16.2M | -5.31M |
| Income tax | 0 | 1 | -1.49M | -199.6K | -193.3K | |
| Net income | -77.9M | -80.6M | -60.4M | -31.2M | -16.2M | -5.31M |
| Earnings per share, basic | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 | -0.41 |
| Earnings per share, diluted | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 41.5M | 39.8M | 36.0M | 29.5M | 99.6M | 1.58M |
| Short-term investments | 77.1M | 139.7M | 91.4M | 98.2M | 0 | |
| Current assets | 120.4M | 181.6M | 129.7M | 132.1M | 100.4M | 1.72M |
| Property, plant and equipment | 4.89M | 4.47M | 3.48M | 2.09M | 290.0K | 59.0K |
| Total assets | 129.7M | 196.6M | 138.3M | 181.2M | 106.6M | 2.19M |
| Accounts payable | 2.28M | 758.0K | 5.05M | 904.0K | 964.0K | 136.0K |
| Current liabilities | 15.7M | 17.2M | 13.3M | 6.52M | 2.91M | 613.0K |
| Total debt | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M | 58.0K |
| Total liabilities | 17.2M | 19.8M | 17.1M | 10.8M | 7.88M | 10.6M |
| Shareholders' equity | 112.5M | 176.8M | 121.2M | 170.5M | -23.8M | -8.41M |
| Shares outstanding | 31.6M | 31.2M | 22.5M | 21.9M | 1.77M | 12.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -63.7M | -65.7M | -42.6M | -30.1M | -14.0M | -2.80M |
| Capital spending | -1.67M | -2.77M | -1.29M | -2.17M | -238.0K | -15.0K |
| Free cash flow | -65.3M | -68.4M | -43.9M | -32.3M | -14.2M | -2.82M |
| Cash from investing | 66.1M | -51.8M | 50.7M | -141.7M | -238.0K | -15.0K |
| Cash from financing | -749.0K | 121.0M | -1.55M | 101.7M | 112.2M | 2.89M |
| Share buybacks | 101.7M | |||||
| Change in cash | 1.69M | 3.59M | 6.52M | -70.1M | 98.0M | 71.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| S-3 · Registration statement | Nov 16, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 23, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 27, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 8-K · Current report | Mar 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
This page holds 200 of 359 filings. Open Filings
Cap table
Built by 6ix from Acrivon Therapeutics, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 42,911,680
- Fully diluted
- 42,911,680
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,911,680 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 42,911,680 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Nov 9, 2022 |
| Ivana Magovčević-Liebisch Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past); Spyre Therapeutics, Inc. (Director · Jun 8, 2021 – Jun 22, 2023 · Past) | Director · Since at least Feb 8, 2024 |
| Derek DiRocco Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); Evommune, Inc. (Board Member · Since at least Nov 4, 2026) | Director · Since at least May 18, 2026 |
| Mansoor Raza Mirza Other companies: Karyopharm Therapeutics Inc. (Director · Since at least May 28, 2025); Sera Prognostics, Inc. (Director · Since at least Apr 7, 2025) | Chief Medical Officer · Since at least Apr 9, 2025 |
| Sharon Shacham Other companies: Nasus Pharma Ltd. (Board Member · Since at least Mar 18, 2026); Karyopharm Therapeutics Inc. (Chief Scientific Officer · Sep 16, 2019 – Mar 29, 2022 · Past) | Director · Since at least Nov 9, 2022 |
| Adam D. Levy Other companies: Mineralys Therapeutics, Inc. (Chief Financial Officer · Since at least Feb 9, 2023) | Chief Financial Officer · Since at least Apr 1, 2025 |
| Mary-Alice Miller Other companies: Butterfly Network, Inc. (General Counsel & Corp Sec · Feb 12, 2021 – Mar 22, 2022 · Past) | Chief Legal Officer · Since at least Sep 26, 2023 |
| Santhosh Palani Other companies: Pyxis Oncology, Inc. (Director · Since at least Mar 12, 2024) | Director · Since at least Mar 4, 2024 |
| Caroline Wigerup | Vice President, Research and Business Operations · Since at least Nov 4, 2026 |
| Charles Baum | Director · Since at least May 20, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Eric Devroe | Chief Operating Officer · Since at least Nov 9, 2022 |
| Erick Gamelin | Chief Development Officer · Since at least Nov 9, 2022 |
| Katharine Peterson | Chief Accounting Officer · Since at least May 13, 2024 |
| Kristina Masson | EVP - Business Operations, Director · Since at least May 21, 2026 |
| Michaela Levin | Chief Business Officer · Since at least Aug 31, 2026 |
| Michael Tomsicek | Director · Since at least May 20, 2026 |
| Peter Blume-Jensen | Director · Since at least Nov 9, 2022 |
Log in to ask 6ix AI your own questions about Acrivon Therapeutics, Inc.